Delivery Order SPE2DB22D3016-SPE2DB25FAZN5
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $11,411.43 under a firm fixed-price contract. The delivery order is non-set-aside and carries an ultimate completion date of September 4, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $10,722.90 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes on June 16, 2025, with an ultimate completion date of June 17, 2025. This firm fixed price, competitively awarded contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,877.84 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract is a firm fixed price delivery order with an ultimate completion date of June 27, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this order from its corporate office location. This delivery order is issued under the company's broader...
- The Defense Logistics Agency awarded a delivery order valued at $2,158.38 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Actemra 162 mg/0.9 mL syringes with a ceiling value of $16,453.58. This is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and no set-aside designation was used in the award. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $11,336.48 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes, with a completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a direct fulfillment order under AmerisourceBergen's broader contract vehicle with DLA. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $19,792.71 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. This firm fixed price, competitively awarded contract was executed on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes on July 14, 2025, with a contract ceiling value of $3,662.95. This order is not set-aside and was competitively awarded under a firm fixed-price arrangement, with an ultimate completion date of July 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $36,593.17. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This is a non-set-aside, competitively awarded contract with a firm fixed price ceiling value of $9,793.69 and a completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FAZN5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,877.84 to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and requires completion by June 17, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle valued through December 2026 that enables the company to supply pharmaceutical products and medical supplies to military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency and military healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to deliver a broad range of pharmaceutical products across multiple therapeutic domains through open competition. This delivery order for Actemra, a biologic medication used to treat rheumatoid arthritis and other inflammatory conditions, reflects the company's ongoing role as a prime vendor in the DLA's pharmaceutical supply chain supporting military and federal healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 6/16/25 |